Medicince introduction including background, function, caution, etc.
Indication Lenvima (lenvatinib) is a kinase inhibitor that is indicated for; Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC. Renal Cell Cancer (RCC): in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy. Hepatocellular Carcinoma (HCC): as first line therapy in patients with unresectable hepatocellular carcinoma. Side Effects Tiredness, joint and muscle pain, weight loss, mouth sores, vomiting 6.stomach (abdomen) pain, decreased appetite, nausea, headache, rash, redness, itching, or peeling of your skin on your hands and feet, Hoarseness. Mechanism of Action In patients with severe renal or hepatic impairment, the dose is 14 mg once daily in DTC and 10 mg once daily in RCC.